Drawing for SKYEPHARMA

USPTO serial 87730607

SKYEPHARMA

Reviewed by CopyMark Law Group

Reg. 5742573Status 710
Filing date
Status date
Registration date
May 7, 2019
Examiner
FRENCH, CURTIS W
Law office
TMO LAW OFFICE 115

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with SKYEPHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

ROBERTA S BREN

ROBERTA S BREN MUNCY GEISSLER OLDS & LOWE PC4000 LEGATO ROAD SUITE 310FAIRFAX, VA 22033UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical additives for use in the manufacture of therapeutic pharmaceuticals, chemical reagents for scientific or medical research use; and chemicals and bio chemicals, namely, enzymes for use in biochemical research and in the diagnostic, agriculture and forestry industries; diagnostic preparations for clinical or medical laboratory useSECTION 8 - CANCELLED—
005[ Dietary supplements for medical and veterinary purposes; ] medical and veterinary plasters, adhesive tapes and adhesive bandages; wound dressings; transdermal patches for use in the timed delivery of drugs, namely, transdermal patches for use in the treatment of diseases and disorders of the central nervous system, cardiovascular system, respiratory system, genito-urinary system, renal system, gastro-intestinal system, liver disorders, immune system, musculo-skeletal and inflammatory disorders, neuromuscular disorders, tuberculosis, and for use in oncology and haematology; surgical dressings and burn dressings; analgesics; bacterial preparations for medical and veterinary purposes for use as anti-infectives; chemical preparations and reagents for the treatment of diseases and disorders of the central nervous system, cardiovascular system, respiratory system, genito-urinary system, renal system, gastro-intestinal system, liver disorders, immune system, musculo-skeletal and inflammatory disorders, neuromuscular disorders, tuberculosis, and for use in oncology and haematology; [ food for medically restricted diets, namely, vitamin-fortified beverages for medical and veterinary uses; nutritionally fortified beverages for medical and veterinary uses; ] pharmaceutical preparations for post-cosmetic surgery for use in the treatment of diseases and disorders of the central nervous system, cardiovascular system, respiratory system, genito-urinary system, renal system, gastro-intestinal system, liver disorders, immune system, musculo-skeletal and inflammatory disorders, neuromuscular disorders, tuberculosis, and for use in oncology and haematology; [ dietary food supplements for medically restricted diets, and diet pills, all for medical and veterinary purposes; ] topical gels, ointments, creams and powder for relief of itching and irritated skin for medical and veterinary purposes; suppositories and unit dose capsules sold empty for pharmaceutical medical and veterinary use; pharmaceuticals having a time release effect for the treatment of diseases and disorders of the central nervous system, cardiovascular system, respiratory system, genito-urinary system, renal system, gastro-intestinal system, liver disorders, immune system, musculo-skeletal and inflammatory disorders, neuromuscular disorders, tuberculosis, and for use in oncology and haematology; anti-inflammatory and anti-bacterial pharmaceuticals for post cosmetic procedure treatments; and surgical implants comprising living tissue; bandages for skin woundsSECTION 8 - CANCELLED—
010Transdermal patches sold without medication for use in the timed delivery of drugs; Surgical, medical, and veterinary apparatus and instruments, namely, surgical scrub suits, masks and gowns, surgical cutlery, medical tubing for irrigation and drainage purposes, wound drainage apparatus; wound mending devices, namely, surgical clips; surgical implants comprising artificial material; inhalers for therapeutic use; medical syringes; needles for medical use; devices for the injection of medicines, namely, hypodermic needles, hypodermic and medical syringes and catheters; apparatus, instruments and devices for storing and dispensing medical, surgical and veterinary preparations, creams, powders, tablets and pills, namely, pharmaceutical containers especially made for storing and dispensing creams, powders, tablets, pills, medical waste, urine and blood, cups for dispensing medicine and medical infusion pumps for dispensing medicines for use in the delivery and control of medical nutritional fluids; containers especially adapted for storing surgical devices, namely, for storing spoons, syringes, suppositories, vials, intravenous sets, inhalers, sprays, and adhesive and medical tapes; replacement parts and fittings for all of the aforesaidSECTION 8 - CANCELLED—
042Medical research and development in the fields of pharmaceutical delivery methods and the development of new pharmaceuticals; research and development of new surgical products for others; veterinary research and development; scientific research and development; new product design services for others; product development; engineering design services for othersSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 21, 2025C8..CANCELLED SEC. 8 (6-YR)—
May 7, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 3, 2022TMBNTTAB RELEASE CASE TO TRADEMARKS—
Jan 3, 2022CANTCANCELLATION TERMINATED NO. 999999—
Dec 24, 2021A7OKAMENDMENT UNDER SECTION 7 - PROCESSED—
Dec 20, 2021CANDCANCELLATION DENIED NO. 999999—
Nov 30, 2021PETCCANCELLATION INSTITUTED NO. 999999—
May 7, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 2, 2019DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Apr 2, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 15, 2019IUCNNOTICE OF ALLOWANCE CANCELLED—
Mar 15, 2019D1BRTEAS DELETE 1(B) BASIS RECEIVED—
Jan 15, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 20, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 20, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 31, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 10, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 10, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Oct 10, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 10, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 10, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 3, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 2, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 2, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 5, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 5, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 5, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 2, 2018DOCKASSIGNED TO EXAMINER—
Jan 10, 2018MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jan 9, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 25, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance